2008.03.18 「OSI Pharmaceuticals Announces That the Prior Revocation of Its European DP-IV Patent Has Been Upheld」

OSI pharmaceuticalsのpress release（SEC filing）によると、

EPO審判部は、OSIが保有する、ジペプチジルペプチダーゼIV（dipeptidyl peptidase IV（DP-IV、DPPIV又はDPP-4））に関する特許のひとつ（EP0896538: USE OF ACTIVITY INHIBITING DIPEPTIDYL EPTIDASE IV EFFECTORS FOR LOWERING THE BLOOD GLUCOSE LEVEL IN MAMMALS; ApplicantはOSIの子会社Prosidion）を無効と判断したとのこと。

本特許クレームは、糖尿病等を治療するためのDP-IV inhibitorの使用をカバーする機能クレームであり、2002年に大手製薬メーカー8社（Novartis, Bristol-Myers Squibb, Takeda, Pfizer, Boehringer Ingelheim, Glaxo, Novo Nordisk, Mitsubishi Tanabe）から異議を申立てられ、約6年間の歳月を費やして今回の審決に至った（Appeal No. T1151/04）。

参考:

• EP0896538 B1 Claims:

  1. The use of activity lowering effectors of dipeptidyl peptidase IV (DP IV) or DP IV-like enzyme activity for the preperation of a medicament for the oral therapy of diseases which are based on glucose concentrations in the serum of mammals characteristic of hyperglycemia.

  2. The use according to claim 1 for the preparation of a medicament for the prevention or alleviation of pathological abnormalities of the metabolism of mammals such as glucosuria, hyperlipidemia, metabolic acidosis and Diabetes mellitus.

  3. The use according to claim 1 or 2, characterized in that inhibitors, pseudosubstrates, inhibitors of DP IV expression, binding proteins, or antibodies against said enzyme proteins or combinations of the designated effectors are used as activity lowering effectors of Dipeptidyl Peptidase IV (DP IV) or DP IV-like enzyme activity.

  4. The use according to any one of the procedeing claims, characterized in that the effectors lower the activity of DP IV or DP IV-like enzyme activity with respect to GIP_1-42 and/or GLP-1_7-36.

  5. The use according to claim 4, characterized in that substrates are used as effectors.

  6. The use according to any one of the preceding claims wherein a combination of effectors is used.

  7. The use according to any one of the preceding claims, characterized in
  that the effectors are alanyl pyrrolidide, isoleucyl thiazolidide, N-valyl-prolyl, O-benzoyl hydroxylamine.

  8. The use according to any one of the preceding claims, characterized in that the effectors are used in combination with at least one carrier substance such as glucose.

• OSI Pharmaceuticals press release: 2008.03.18 Pharmaceuticals Announces That the Prior Revocation of Its European DP-IV Patent Has Been Upheld
• Wikipedia: Dipeptidyl peptidase-4; Dipeptidyl peptidase-4 inhibitors